Table 2.

Treatment and outcome of the patients

	Patients (n = 40)
Treatment
Treatment with nasal canula/face mask	n = 37 (92.5%)
Nasal high flow therapy	n = 6 (15%)
Mechanical ventilation, n(%)	n = 12 (30%)
Number of days (IQR)	16 (11–22)
Prone ventilation	n = 11 (27.5%)
Medium care unit admission	n = 1 (2.5%)
Intensive care unit admission	n = 14 (35%)
Days of admission (IQR)	14 (9–24)
Diagnosed in hospital complications
Acute heart failure	n = 3 (7.5%)
Type 1 myocardial infarction	n = 0 (0%)
Type 2 myocardial infarction	n = 1 (2.5%)
Myocarditis	n = 0 (0%)
Ventricular arrythmia	n = 0 (0%)
Atrial fibrillation	n = 3 (7.5%)
CVA/TIA	n = 2 (5%)
Pulmonary embolism	n = 7 (17.5%)
Acute kidney failure	n = 3 (7.5%)
Discharge
Duration of hospital admission (days)	9 (7–22)
Complications after discharge
Days of follow-up after first TTE (IQR)	200 (191–206)
Pulmonary embolism	n = 2 (%)
Myocardial infarction	n = 0 (0%)
Acute heart failure	n = 0 (0%)
Atrial fibrillation	n = 1 (2.5%)
Myocarditis	n = 0 (0%)
Hospitalization for cardiac cause	n = 0 (0%)
Emergency department visit	n = 1 (2.5%)
Deceased	n = 0 (0%)
Self-reported symptoms after COVID-19*
Dyspnea	n = 11 (27.5%)
Chest pain	n = 3 (7.5%)
Peripheral edema	n = 3 (7.5%)
Fatigue	n = 7 (17.5%)

Values are in median and interquartile range, or n (%)

CVA cerebrovascular accident, TIA transient ischaemic attack, TTE transthoracic echocardiogram

*symptoms assessed by online questionnaire at 200 days (IQR; 191–206) after TTE